Edgemont Pharmaceuticals has launched a new formulation dose of bupropion extended-release tablets in a strength of 450mg dose.
The Forfivo XL, which the company claims, is the only available 450mg dose of an extended-release bupropion product and is intended for the treatment of major depressive disorder (MDD).
Edgemont Pharmaceuticals president and CEO Douglas Saltel said until now, most patients in the US requiring a 450mg dose of bupropion have been taking multiple tablets to achieve their dose requirement.
"We are very pleased to be able to simplify the dosing regimen for these patients to a single Forfivo XL 450mg tablet once-daily," Saltel added.
The company said Bupropion Hcl is marketed under several dosage forms and brand names including Wellbutrin, Wellbutrin SR and Wellbutrin XL.
